Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

BACKGROUND The aberrant activation of the PI3K/mTOR signaling circuitry is one of the most frequently dysregulated signaling events in head and neck squamous cell carcinoma (HNSCC). Here, we conducted a single-arm, open-label phase IIa clinical trial in individuals with oral premalignant lesions (OP...

Full description

Bibliographic Details
Main Authors: J. Silvio Gutkind, Alfredo A. Molinolo, Xingyu Wu, Zhiyong Wang, Daniela Nachmanson, Olivier Harismendy, Ludmil B. Alexandrov, Beverly R. Wuertz, Frank G. Ondrey, Denise Laronde, Leigha D. Rock, Miriam Rosin, Charles Coffey, Valerie D. Butler, Lisa Bengtson, Chiu-Hsieh Hsu, Julie E. Bauman, Stephen M. Hewitt, Ezra E.W. Cohen, H-H. Sherry Chow, Scott M. Lippman, Eva Szabo
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-09-01
Series:JCI Insight
Subjects:
Clinical trials
Online Access:https://doi.org/10.1172/jci.insight.147096

Internet

https://doi.org/10.1172/jci.insight.147096

Similar Items